Grifols, S.A.

GRF

ES0171996087

Pharmaceuticals

Real-time Estimate Tradegate Other stock markets 11:01:27 19/01/2026 GMT			5-day change	1st Jan Change
10.58 ^EUR	-2.89%		-4.33%	-0.89%

01-16	Spanish stocks - Factors to watch on Jan 16	RE
01-15	European Equities Traded in the US as American Depositary Receipts Little Changed in Thursday Trading	MT

Grifols approves an interim dividend payment

Published on 07/29/2025 at 05:29 pm BST

Acquiremedia

Grifols, S.A.

-2.89%

GRIFOLS, S.A.

This announcement has been issued through the Companies Announcement Service of Euronext Dublin.

To view the announcement in full, please click https://newsserviceweb.oslobors.no/message/78599.

Latest news about Grifols, S.A.

01-16	Spanish stocks - Factors to watch on Jan 16	RE
01-15	European Equities Traded in the US as American Depositary Receipts Little Changed in Thursday Trading	MT
01-14	European Equities Traded in the US as American Depositary Receipts Rise in Wednesday Trading	MT
01-09	European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading	MT
01-08	Grifols, S.A. Announces Board Changes, Effective January 1, 2026	CI
12-26	European Equities Traded in the US as American Depositary Receipts Little Changed in Friday Trading; Gains 2% for Week	MT
12-24	European Equities Traded in the US as American Depositary Receipts Rise in Wednesday Trading	MT
12-24	Spanish stocks - Factors to watch on Dec 24	RE
12-19	Grifols Wins US FDA Approval for Rare Blood Disorder Drug Fesilty	MT
12-19	Grifols gets FDA approval for new fibrinogen concentrate, Fesiltytm	RE
12-19	Biotest AG Announces US FDA Approval of Grifols' Fesilty?? (fibrinogen, Human-Chmt)	CI
12-16	European Medicines Agency Grants Compliance Certification for Plasma Supplied by Grifols Egypt	MT
12-16	Grifols gets EMA approval for manufacture and selling of Egyptian plasma	RE
12-04	Grifols achieves self-sufficiency in plasma-derived medicines in Egypt	RE
12-03	European Equities Traded in the US as American Depositary Receipts Higher in Wednesday Trading	MT
11-18	Grifols Says it Gets US FDA's Expanded Indication for Thrombate III for Pediatric Patients	MT
11-18	Grifols gets FDA approval for Thrombate III in pediatric patients in U.S.	RE
11-14	European Equities Traded in the US as American Depositary Receipts Decline in Friday Trading	MT
11-13	European Equities Traded in the US as American Depositary Receipts Slightly Higher in Thursday Trading	MT
11-13	Grifols gets regulatory approval for fibrinogen concentrate in Germany	RE
11-13	Spanish stocks - Factors to watch on Nov 13	RE
11-12	Grifols secures 95% of investor support to improve documentation terms of its 1.3 bln euros secured notes	RE
11-07	Fitch Maintains Grifols' Ratings, Changes Outlook to Positive	MT
11-06	European Equities Traded in the US as American Depositary Receipts Decline in Thursday Trading	MT
11-06	Grifols lifts 2025 targets but fibrinogen delay and forex drag weigh on outlook

Grifols, S.A. specializes in the research, development, manufacturing and marketing of therapeutic products and medical devices for use in hospitals and medical analysis laboratories. Net sales break down by family of products and services as follows: - products derived from plasma (85.2%): products for use by the pharmaceutical and biotechnology industries; - diagnostic machines and reagents (8.9%): in vitro hemophilic diagnostic equipment, coagulation analyzers, infectious serology reagents, etc. for use primarily by blood banks and transfusion centers; - hospital products (3%): non-biological surgical products, radiology and nutritional products, etc. for use by hospital pharmacies; - other (2.9%): primarily intermediate biological products and subcontracted manufacturing services. Net sales are distributed geographically as follows: Spain (5.9%), European Union (15.5%), the United States and Canada (56.7%) and other (21.9%).

Employees

23,800

Sector

Pharmaceuticals

Calendar

02-25 - Q4 2025 Earnings Release (Projected)

More about the company